Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416670 | 0.70 | HSD17B10 (0.44) | FDPS | |
| SCHEMBL27957475 | 0.69 | CYP1A2 (0.40) | FDPSALDH1A1 | |
| SCHEMBL30539287 | 0.68 | ADORA2A (0.47) | FDPSALDH1A1HDAC1HDAC6 | |
| SCHEMBL28186936 | 0.68 | FDPS (0.43) | FDPSMKNK2ALDH1A1HDAC1HDAC6 | |
| SCHEMBL14993002 | 0.68 | FDPS (0.43) | FDPSMKNK2ALDH1A1HDAC1HDAC6 | |
| SCHEMBL754943 | 0.68 | ADORA2A (0.47) | FDPSALDH1A1HDAC1HDAC6 | |
| SCHEMBL27531816 | 0.68 | FDPS (0.39) | FDPSMKNK2ALDH1A1HDAC1HDAC6 | |
| SCHEMBL1748495 | 0.67 | FDPS (0.37) | FDPSMKNK2ALDH1A1HDAC1HDAC6 | |
| SCHEMBL2451018 | 0.66 | FDPS (0.44) | FDPSMKNK2ALDH1A1HDAC1HDAC6 | |
| SCHEMBL11611670 | 0.65 | FDPS (0.38) | FDPSMKNK2ALDH1A1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, MTMR1 | FDPS 352/4885MKNK2 292/4885ALDH1A1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.